Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2001-10-25
2009-11-10
Wehbe, Anne Marie S (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100
Reexamination Certificate
active
07615537
ABSTRACT:
The present invention relates to a method of treating an individual having a blood coagulation defect (e.g., hemophilia A, hemophilia B), comprising administering to the individual an effective amount of a DNA vector encoding modified Factor VII (FVII), wherein the modified Factor VII leads to generation of Factor VIIa in vivo. In a particular embodiment, the invention pertains to a method of treating an individual having a blood coagulation defect comprising administering to the individual an effective amount of a nucleic acid encoding a modified FVII wherein the modified FVII comprises a signal which codes for precursor cleavage by furin at the activation cleavage site of the modified FVII. The invention also relates to a method of treating an individual having a blood coagulation disorder comprising administering to the individual an effective amount of a nucleic acid encoding the light chain of human FVII and a nucleic acid encoding the heavy chain of human FVII operably linked to a leader sequence. Compositions, expression vectors and host cells comprising nucleic acid which encodes a modified Factor VII, wherein the modified Factor VII leads to generation of Factor VIIa in vivo is also encompassed by the present invention.
REFERENCES:
patent: 4784950 (1988-11-01), Hagen et al.
patent: 5739101 (1998-04-01), Roy et al.
patent: 5824639 (1998-10-01), Berkner
patent: 6210929 (2001-04-01), Schlokat et al.
patent: 2003/0192066 (2003-10-01), Zhang et al.
patent: 0775750 (1997-05-01), None
patent: WO 97/20043 (1997-06-01), None
patent: WO 00/23116 (2000-04-01), None
patent: WO 01/70763 (2001-09-01), None
U.S. Appl. No. 60/191,331, filed Sep. 2001, Hish et al.
Margaritis et al., Blood, vol. 98, No. 11, Par 1, pp. 696a, abstract # 2908, Nov. 16, 2001.
Manno, Semin Hematol 40 (suppl 3):23-28, 2003.
Greengard et al., Thrombosis and Haemostasis, vol. 82, 2:555-561, 1999.
VandenDriessche et al., Current Gene Therapy, 1:301-315, 2001.
Seidah et al. (1999) Brain Research, vol. 848, 45-62.
Miller, G. et al., “Expression of factor VII by muscle cells in vitro and in vivo following direct gene transfer: modelling gene therapy for haemophilia”, Gene Therapy, vol. 2, No. 10: pp. 736-742, Dec. 1, 1995.
Shah, A.M. et al.. “Manipulation of the membrane binding site of vitamin K-dependent proteins: Enchanced biolgoical function of human factor VII”, Proceedings of the National Academy of Sciences, USA, vol. 95, No. 8: pp. 4229-4234, Apr. 14, 1998.
Arkin S. et al., “Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors: Results of the NovoSeven emergency-use program”, Database Biosis Online, Biosciences Information Service, Database Accession No. PREV1999900229958 XP002228408 abstract & Haemostasis, vol. 28, No. 2: pp. 93-98, Mar. 1998.
Roman, Drews et al., “Proteolytic maturation of protein C upon engineering the mouse mammary gland to express furin”, Database Biosis Online, Biosciences Information Service, Database Accession No. PREV199698601105 XP 002228409 abstract & Proceedings of the National Academy of Sciences of the United States, vol. 92, No. 23: pp. 10462-10466, 1995.
Hart, C E et al., “Characterization of a cDNA coding for human factor VII”, Database Medline Online, Database Accession No. NLM3486420 XP002228410 abstract & Proc Natl Acad Sci, USA. vol. 83, pp. 2412-2416, 1986.
Paris, Margaritis et al., “Long-term expression of activated FVII in vivo following AAV-mediated liver gene transfer: Implications for treatment with continuous infusion of recombinant activated FVII”, Database Biosis Online, Biosciences Information Service, Database Accession No. PREV200200220527 XP 002228411 abstract Blood, vol. 98, No. 11, Part 1, pp. 696a, Nov. 16, 2001.
Scaria Abraham
Wadsworth Samuel C.
Genzyme Corporation
Wehbe Anne Marie S
LandOfFree
Methods for treating blood coagulation disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating blood coagulation disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating blood coagulation disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4144243